Navigation Links
Alimera Sciences Names European Management Team
Date:11/14/2012

St. Helens and Knowsley School of Nursing, Merseyside, a renal and urology specialist nursing degree from Oxford School of Nursing, Oxford, and a Bachelor of Arts in health studies from Oxford Brookes University.

About ILUVIEN®

ILUVIEN (190 micrograms fluocinolone acetonide intravitreal implant in applicator) is a sustained release intravitreal implant used to treat patients with chronic DME considered insufficiently responsive to available therapies. Each ILUVIEN implant provides a therapeutic effect of up to 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide (FAc). ILUVIEN is injected in the back of the patient's eye to a position that takes advantage of the eye's natural fluid dynamics. The applicator employs a 25-gauge needle, which allows for a self-sealing wound. In Alimera's FAME Study, the most frequently reported adverse drug reactions included cataract operation, cataract and increased ocular pressure.

In July 2010, Alimera submitted a Marketing Authorization Application (MAA) to seven European countries via the Decentralized Procedure (DCP) with the Medicines and Healthcare products Regulatory Agency of the U.K. (MHRA) serving as the Reference Member State (RMS). The MAA included data from two Phase 3 pivotal clinical trials for ILUVIEN conducted by Alimera (collectively known as the FAME Study). The trials involved 956 patients in sites across the United States, Canada, Europe and India to assess the efficacy and safety of ILUVIEN for the treatment of DME. At the end of the DCP, a consensus was reached by the RMS and the other six countries that the MAA for ILUVIEN was approvable. To date, five of the seven countries, Austria, the United Kingdom, Portugal, France and Germany, have granted national licenses for ILUVIEN. ILUVIEN has not been approved by the United States Food and Drug Administration.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Geo
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference
2. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
8. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
9. Neurocrine Biosciences Reports First Quarter 2012 Results
10. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
11. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
(Date:4/21/2014)... EAST LANSING, Mich. --- The most effective way ... at the start and keep them from growing. ... the Journal of Biological Chemistry , shows ... clumping, or aggregating, the first step of neurological ... Huntington,s disease. , The results are pushing the ...
(Date:4/20/2014)... A single type of cell in the lining ... invasive bladder cancer, according to researchers at the Stanford ... mice, is the first to pinpoint the normal cell ... It,s also the first to show that most bladder ... one cell, and explains why many human bladder cancers ...
(Date:4/18/2014)... a discovery that turns 160 years of neuroanatomy on ... known to be essential for the fast transmission of ... as ubiquitous as thought, according to a new work ... Cell Institute (HSCI) and the University,s Department of Stem ... Lichtman, of Harvard,s Department of Molecular and Cellular Biology. ...
(Date:4/18/2014)... made a brain-related discovery that could revolutionize doctors, ... discovery opens up the possibility that environmental and/or ... brain activity that the researchers have identified as ... of Neuroscience has just published a paper ... professor of psychology and his doctoral student John ...
(Date:4/17/2014)... PHILADELPHIA The presence of chronic inflammation in ... aggressive, prostate cancer, and this association was found ... levels, according to a study published in ... of the American Association for Cancer Research. , ... some participants of the placebo arm of the ...
Breaking Medicine News(10 mins):Health News:MSU physicists push new Parkinson's treatment toward clinical trials 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... for Cryopreservation of Cell-Based ... Melanoma Therapy, ... BLFS), a leading developer and marketer of,proprietary hypothermic storage and cryopreservation ... the,adoption of its products in the cellular therapy and cord blood ...
... Reesman, RN, Executive,Director, Passport Health Colorado, says far too ... types, leave,home without taking the basic steps she suggests ... into their health as they do into their,destination choice, ... 1) Get advice from a travel health professional. ...
... new standards, LENEXA, Kan., Mar. 26 ... of ClosedLoop(TM) clinical systems for,blood and medication management, ... Transfusion software for hospital,blood banks and LifeTrak(R) software ... global blood labeling standards being required in the,United ...
... 2008 Resources for Voters on Health Care and,Social ... Academy of,Actuaries said the most recent Medicare trustees, ... long-term financing issues.,According to the program,s trustees, Medicare,s ... taxes, and Medicare must,rely also on interest accrued ...
... Spheris, a leading global,outsource provider of clinical documentation technology ... months ended December 31, 2007., Financial Highlights-Fourth Quarter ... of 2007 were $48.6 million compared,with $51.4 million in ... net revenues during the fourth quarter of 2007 from ...
... March 26 FluoroPharma Inc., a company,developing ... Emission,Tomography (PET) market, announced that it has ... Hospital (MGH) for the development and,commercialization of ... (AD). The licensed technologies, which were co-developed ...
Cached Medicine News:Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 2Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 3Health News:The Top Ten Health Tips for International Travel 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 3Health News:Medicare Trustees' Report Highlights Need for Reform 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 3Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 4Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 5Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 6Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 7Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 8Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 9Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 10Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 11Health News:FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease (AD) 2
... the quantitative determination of Immunoglobulin E ... atopic allergic diseases such as atopic ... been shown to exhibit increased total,immunoglobulin ... is also known as the,reagenic antibody. ...
...
...
...
Medicine Products: